Illuminating the Druggable Genome (IDG) NCATS Advisory Council - PowerPoint PPT Presentation

Illuminating the Druggable Genome (IDG) NCATS Advisory Council and CAN Review Board Meeting September 15, 2016 Christine Colvis, Ph.D. Director, New Therapeutics Program, NCATS

2

IDG Team Chairs Working Group Members • Christopher Austin, NCATS • Mehdi Mesri, NCI • Griffin Rodgers, NIDDK • Ravi Ravichandran, NCI Coordinators • Mat t Reilly, NIAAA • Antonio Noronha, NIAAA • Aaron Pawlyk, NIDDK • Dwayne Lunsford, NIDCR • Christine Colvis, NCATS • Kris Bough, NIDA Project Team Leaders • Iddil Bekirov, NIDDK • Colin Fletcher, NHGRI • Yong Yao, NIMH (Tech Dev) • Zorina Galis, NHLBI • Jean C. Zenklusen, NCI (KMC) • Anne Zaj icek, NICHD Project Scientists • Miles Fabian, NIGMS • Ajay Pillai, NHGRI • J. Randy Knowlton, NCI • Margaret Sutherland, NINDS • Enrique Michelotti, NIMH • Corinne S ilva, NIDDK OSC External Scientific Panel • Gurusingham S it t ampalam, NCATS • Mary Perry • Rommie Amaro, UCS D • Bobbi Gardner, NCATS Marishka Brown • • Andrew Hopkins, Univ. Dundee • Margaret S utherland, NINDS • Aron Marquitz • Peter S orger, Harvard • Katerina Tsilou, NICHD • • Xin (Jean) Yuan, OP A Dwight Towler, UT S outhwestern 3

The IDG Challenge Tendency to study what’s known 10% drugged 3,000 genes in the druggable genome – 90% not BRAF exploited! Nature Reviews Drug Discovery, 2002 4

IDG - Pilot Phase (August 2014-August 2017) IDG Pilot Phase Goals: • Develop ability to identify, classify, and prioritize understudied proteins (G- protein coupled receptors, ion channels, protein kinases, & nuclear receptors) • Demonstrate scalability of technologies needed for large-scale illumination Scalable Technology Knowledge Management Adaptation (FY14-16) Center (FY14-16) • Integrate existing data and make it • Medium- to high-throughput, searchable through a single portal scalable assays to explore • Define current state of function of protein families knowledge/ ignorance • New tools to facilitate • Prioritize proteins for illumination experiments at needed scale Strong interest from pharma. Seven pharmaceutical companies attended our consortium meeting in March 2016

IDG - Implementation Phase Funding Opportunity Announcements Coming t his f all 1) Expand the informatics tools developed in the pilot phase to include additional data and allow users to access a wide range of information on sets of proteins; 2) Elucidate the function of understudied proteins from key druggable protein families; and 3) Disseminate the IDG-generated resources and data to the greater scientific community.